Downregulation of LGI1 promotes tumor metastasis in esophageal squamous cell carcinoma

Carcinogenesis

Volumn 35, Issue 5, 2014, Pages 1154-1161

  Zhu, Ying Hui ^a   Liu, Haibo ^b   Zhang, Li Yi ^c   Zeng, Tingting ^a   Song, Ye ^a   Qin, Yan Ru ^d   Li, Lei ^a   Liu, Lulu ^a   Li, Jianbiao ^a   Zhang, Baozhu ^a   Guan, Xin Yuan ^a,c  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE C; STROMELYSIN;

ADULT; ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CARCINOGENICITY; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CLONOGENESIS; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DOWN REGULATION; ENZYME PHOSPHORYLATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LEUCINE RICH GLIOMA INACTIVATED 1 GENE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROTEINS; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEINS;

EID: 84901984673     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu040     Document Type: Article

References (36)

1. Kamangar, F. et al. (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol., 24, 2137-2150.
2. Wheeler, J.B. et al. (2012) Epidemiology of esophageal cancer. Surg. Clin. North Am., 92, 1077-1087.
3. Hongo, M. et al. (2009) Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity. J. Gastroenterol. Hepatol., 24, 729-735.
4. Stoner, G.D. et al. (2001) Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis, 22, 1737-1746.
5. Xiao, Z.F. et al. (2003) Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann. Thorac. Surg., 75, 331-336.
6. Shimizu, K. et al. (2005) Clinical evaluation of low-dose cisplatin and 5-fluorouracil as adjuvant chemoradiotherapy for advanced squamous cell carcinoma of the esophagus. Hiroshima J. Med. Sci., 54, 67-71.
7. Hagymási, K. et al. (2009) Risk factors for esophageal cancer, and possible genetic background. Orv. Hetil., 150, 407-413.
8. He, L.R. et al. (2009) Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci., 100, 1591-1596.
9. Yuen, H.F. et al. (2008) DJ-1 could predict worse prognosis in esophageal squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev., 17, 3593-3602.
10. Vogelstein, B. et al. (1988) Genetic alterations during colorectal-tumor development. N. Engl. J. Med., 319, 525-532.
11. Chernova, O.B. et al. (1998) A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors. Oncogene, 17, 2873-2881.
12. Buchanan, S.G. et al. (1996) Structural and functional diversity in the leucine-rich repeat family of proteins. Prog. Biophys. Mol. Biol., 65, 1-44.
13. Cowell, J.K. et al. (2010) Inactivation of LGI1 expression accompanies early stage hyperplasia of prostate epithelium in the TRAMP murine model of prostate cancer. Exp. Mol. Pathol., 88, 77-81.
14. Besleaga, R. et al. (2003) Expression of the LGI1 gene product in astrocytic gliomas: downregulation with malignant progression. Virchows Arch., 443, 561-564.
15. Fialka, F. et al. (2008) CPA6, FMO2, LGI1, SIAT1 and TNC are differentially expressed in early- and late-stage oral squamous cell carcinoma-a pilot study. Oral Oncol., 44, 941-948.
16. Shimada, Y. et al. (1992) Characterization of 21 newly established esophageal cancer cell lines. Cancer, 69, 277-284.
17. Xie, D. et al. (2003) Heterogeneous expression and association of betacatenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int. J. Cancer, 107, 896-902.
18. Roy, R. et al. (2009) Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol., 27, 5287-5297.
19. Westermarck, J. et al. (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J., 13, 781-792.
20. Reunanen, N. et al. (2002) Activation of p38 alpha MAPK enhances collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization. J. Biol. Chem., 277, 32360-32368.
21. Rommel, C. et al. (1999) Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science, 286, 1738-1741.
22. Besson, A. et al. (2001) Differential activation of ERKs to focal adhesions by PKC epsilon is required for PMA-induced adhesion and migration of human glioma cells. Oncogene, 20, 7398-7407.
23. Kunapuli, P. et al. (2003) Suppression of the cell proliferation and invasion phenotypes in glioma cells by the LGI1 gene. Oncogene, 22, 3985-3991.
24. Kunapuli, P. et al. (2004) LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway. J. Biol. Chem., 279, 23151-23157.
25. Samantaray, S. et al. (2004) Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J. Cancer Res. Clin. Oncol., 130, 37-44.
26. Mukherjee, S. et al. (2010) Increased matrix metalloproteinase activation in esophageal squamous cell carcinoma. J. Transl. Med., 8, 91.
27. Ohashi, K. et al. (2000) Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer, 88, 2201-2209.
28. Islekel, H. et al. (2007) Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables. Cell Biochem. Funct., 25, 433-441.
29. Kähäri, V.M. et al. (1997) Matrix metalloproteinases in skin. Exp. Dermatol., 6, 199-213.
30. Shapiro, S.D. (1998) Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr. Opin. Cell Biol., 10, 602-608.
31. Staub, E. et al. (2002) The novel EPTP repeat defines a superfamily of proteins implicated in epileptic disorders. Trends Biochem. Sci., 27, 441-444.
32. Scheel, H. et al. (2002) A common protein interaction domain links two recently identified epilepsy genes. Hum. Mol. Genet., 11, 1757-1762.
33. Kunapuli, P. et al. (2010) Reexpression of LGI1 in glioma cells results in dysregulation of genes implicated in the canonical axon guidance pathway. Genomics, 95, 93-100.
34. Head, K. et al. (2007) Defining the expression pattern of the LGI1 gene in BAC transgenic mice. Mamm. Genome, 18, 328-337.
35. Ribeiro, P.A. et al. (2008) Expression profile of Lgi1 gene in mouse brain during development. J. Mol. Neurosci., 35, 323-329.
36. Krex, D. et al. (2002) Physical and functional characterization of the human LGI1 gene and its possible role in glioma development. Acta Neuropathol., 103, 255-266.